Phase I Trial of IV Fenretinide (4-HPR) Plus IV Safingol for Patients With Relapsed Malignancies
Phase I Trial of Intravenous Fenretinide (4-HPR) Plus Intravenous Safingol for Patients With Relapsed Malignancies
Sponsor: South Plains Oncology Consortium
Terminated
drug supply issues during COVID-19
Other terminated trials from South Plains Oncology Consortium
- Neuroblastoma · Phase PHASE1 · May 2018
- Acute Lymphoblastic Leukemia · Phase PHASE1 · Apr 2018
- Cancer of Ovary · Phase PHASE1/PHASE2 · Jun 2017
More terminations from South Plains Oncology Consortium
Other Solid Tumor trials with similar outcome
A PHASE1 clinical study on Solid Tumor, this trial is terminated or withdrawn. The trial is conducted by South Plains Oncology Consortium and has accumulated 10 data snapshots since 2016. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Apr 2022 — Jul 2024 [monthly]
Terminated PHASE1
Status: Unknown Status → Terminated
-
Oct 2021 — Apr 2022 [monthly]
Unknown Status PHASE1
Status: Recruiting → Unknown Status
-
Jan 2021 — Oct 2021 [monthly]
Recruiting PHASE1
▶ Show 5 earlier versions
-
Oct 2019 — Jan 2021 [monthly]
Recruiting PHASE1
-
Jun 2018 — Oct 2019 [monthly]
Recruiting PHASE1
-
Dec 2017 — Jun 2018 [monthly]
Recruiting PHASE1
-
Feb 2017 — Dec 2017 [monthly]
Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Nov 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- South Plains Oncology Consortium
For direct contact, visit the study record on ClinicalTrials.gov .